Vision Mission & Strength
R & D
Niprolac Oral Sol
Starcal D Forte
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
NIPRO JMI Pharma Limited (NJP) has introduced Linagliptin (Lijenta) and Empagliflozin (Empa), which are the breakthroughs in diabetic management and aiding millions of diabetic patients in the country....
NIPRO JMI Pharma Ltd. has celebrated Bangla New Year - 1426 at Corporate office....
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
Acetylcysteine is a mucolytic agent that reduces the viscosity of secretions probably by the
splitting of disulphide bonds in mucoproteins. Moreover it gives antisecretory effect. These
results in clearing of respiratory ducts and facilitate breathing. Acetylcysteine also has
anti-oxidant properties by reacting with free radicals and also by serving as a precursor to
glutathione, which is an important intra and extra-cellular antioxidant. By providing
anti-oxidant action, it neutralizes exogenous and endogenous oxidants, which in fact act as
pathogens in respiratory inflammations.